Home / News / India News / Article /
Serum Institute gets DCGI nod for clinical trials of Oxford vax
Updated On: 03 August, 2020 11:48 AM IST | New Delhi | IANS
The SII received approval by the Indias top drug regulator on Sunday after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19

This image has been used for representational purposes only
The Drugs Controller General of India (DCGI) has given approval to Pune's Serum Institute of India (SII) to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.
The SII received approval by the India's top drug regulator on Sunday after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

